U.S. patent application number 15/094734 was filed with the patent office on 2017-03-09 for composition exhibiting a von willebrand factor (vwf) protease activity comprising a polypeptide chain with the amino acid sequence aaggilhlellv.
The applicant listed for this patent is Baxalta GmbH, Baxalta Incorporated. Invention is credited to Gerhard Antoine, Miha Furlan, Randolf Kerschbaumer, Bernhard Laemmle, Helena Elisabeth Schaller-Gerritsen, Friedrich Scheiflinger, Hans-Peter Schwarz, Luigina Tagliavacca, Peter Turecek, Klaus Zimmermann.
Application Number | 20170065686 15/094734 |
Document ID | / |
Family ID | 27110398 |
Filed Date | 2017-03-09 |
United States Patent
Application |
20170065686 |
Kind Code |
A1 |
Laemmle; Bernhard ; et
al. |
March 9, 2017 |
Composition Exhibiting a von Willebrand Factor (vWF) Protease
Activity Comprising a Polypeptide Chain with the Amino Acid
Sequence AAGGILHLELLV
Abstract
The invention relates to vWF cleaving entities having a
molecular weight of 180 kD, 170 kD, 160 kD, 120 kD or 110 kD and an
N-terminal amino acid sequence of AAGGILHLELLV, vWF cleaving
complexes and methods for their production.
Inventors: |
Laemmle; Bernhard;
(Bolligen, CH) ; Schaller-Gerritsen; Helena
Elisabeth; (Muri AG, CH) ; Furlan; Miha; (Bem,
CH) ; Turecek; Peter; (Klosterneuburg, AT) ;
Schwarz; Hans-Peter; (Vienna, AT) ; Scheiflinger;
Friedrich; (Vienna, AT) ; Antoine; Gerhard;
(Gross Enzersdorf, AT) ; Kerschbaumer; Randolf;
(Klosterneuburg, AT) ; Tagliavacca; Luigina;
(Milano, IT) ; Zimmermann; Klaus; (Vienna or
Pressbaum, AT) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Baxalta Incorporated
Baxalta GmbH |
Bannockburn
Glattpark (Opfikon) |
IL |
US
CH |
|
|
Family ID: |
27110398 |
Appl. No.: |
15/094734 |
Filed: |
April 8, 2016 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14247116 |
Apr 7, 2014 |
9309506 |
|
|
15094734 |
|
|
|
|
12032553 |
Feb 15, 2008 |
8703426 |
|
|
14247116 |
|
|
|
|
11166288 |
Jun 23, 2005 |
7501117 |
|
|
12032553 |
|
|
|
|
09833328 |
Apr 12, 2001 |
6926894 |
|
|
11166288 |
|
|
|
|
09721254 |
Nov 22, 2000 |
|
|
|
09833328 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61P 9/00 20180101; A61K
38/00 20130101; A61K 38/4886 20130101; C07K 14/755 20130101; C12Y
304/24087 20130101; C12N 9/6416 20130101; C07K 16/36 20130101; C12N
9/6489 20130101; A61P 7/02 20180101 |
International
Class: |
A61K 38/48 20060101
A61K038/48 |
Claims
1. An pharmaceutical composition comprising an effective dose of a
recombinant polypeptide for the treatment of a disease in which the
patient has a supranormal vWF content or an increased level of
high-molecular weight vWF, wherein the polypeptide exhibits vWF
protease activity and vWF binding activity, is produced in an in
vitro mammalian cell culture system, and has a molecular weight
between about 180 kD and about 120 kD as determined by SDS-PAGE
under reducing conditions and comprising the amino acid sequence
TABLE-US-00009 (SEQ ID NO: 4)
AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPS
LGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPE
DDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCL ITEDTGFDLGVTI.
2. The pharmaceutical composition of claim 1, wherein the in vitro
mammalian cell culture system is a CHO cell culture system.
3. The pharmaceutical composition of claim 1, wherein the disease
is thrombotic thrombocytopenic purpura (TTP), Henoch-Schonlein
purpura, preeclampsia, neonatal thrombocytopenia, or
hemolytic-uremic syndrome.
4. The pharmaceutical composition of claim 1, wherein the
recombinant polypeptide comprises the amino acid sequence:
TABLE-US-00010 (SEQ ID NO: 4)
AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPS
LGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPE
DDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCL ITEDTGFDLGVTI.
5. The pharmaceutical composition of claim 3, wherein the disease
is thrombotic thrombocytopenic purpura (TTP), Henoch-Schonlein
purpura, preeclampsia, neonatal thrombocytopenia, or
hemolytic-uremic syndrome.
6. A method of treating a disease in which a patient has a
supranormal vWF content or an increased level of high-molecular
weight vWF, wherein the method comprises administering a
pharmaceutical composition comprising an effective dose of an
isolated polypeptide that has vWF protease activity and comprises a
peptide chain that has a molecular weight from about 180 kD to
about 120 kD as determined by SDS-PAGE under reducing conditions
and comprises the amino acid sequence TABLE-US-00011 (SEQ ID NO: 4)
AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRDPS
LGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPE
DDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCL ITEDTGFDLGVTI.
7. The method of claim 7, wherein the disease is thrombotic
throbocytic purpura (TTP), Henoch-Schonlein purpura, preeclampsia,
neonatal thrombocytopenia or hemolyticuremic syndrome.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of U.S. application Ser.
No. 14/247,116 filed Apr. 7, 2014, which is a divisional of U.S.
application Ser. No. 12/032,553 filed Feb. 15, 2008 (now U.S. Pat.
No. 8,703,426 issued Apr. 22, 2014), which is a divisional of U.S.
application Ser. No. 11/166,288 filed Jun. 23, 2005 (now U.S. Pat.
No. 7,501,117 issued Mar. 10, 2009), which is a continuation of
U.S. application Ser. No. 09/833,328 filed Apr. 12, 2001 (now U.S.
Pat. No. 6,926,894 issued Aug. 9, 2005), which is a
continuation-in-part of application Ser. No. 09/721,254 filed Nov.
22, 2000 (abandoned), all of which are herein incorporated by
reference.
FIELD OF THE INVENTION
[0002] The invention relates to a vWF protease-containing
composition which includes a potypeptide comprising the amino add
sequence AAGGILHLELLV, as well as to nucleotide sequences coding
for such a polypeptide. It further relates to methods for
increasing the stability of the vWF protease.
BACKGROUND OF THE INVENTION
[0003] vWF is a glycoprotein circulating in plasma as a series of
multimers ranging in size from about 500 to 20,000 kD. Multimeric
forms of vWF are composed of 250 kD polypeptide subunits linked
together by disulfide bonds. vWF mediates the initial platelet
adhesion to the subendothelium of a damaged vessel wall, though
only the largest multimers appear to exhibit haemostatic activity.
Such vWF multimers having large molecular masses are stored in the
Weibel Palade bodies of endothelial cells, and it is believed that
endothelial cells secrete these large polymeric forms of vWF. Those
forms of vWF which have a low molecular weight (low molecular
weight or LMW vWF) are believed to arise from proteolytic cleavage
of the larger multimers.
[0004] A small portion of the vWF present in normal plasma
circulates as 189, 176 and 140 kD fragments resulting from
proteolytic degradation of vWF in vivo, the 140 kD fragment being
derived from the N-terminal region, and the 176 kD fragment from
the C-terminal region of the subunit. When LMW forms of vWF are
isolated from normal human plasma and subjected to SDS-PAGE
(polyacrylamide gel electrophoreses) after disulfide reduction, an
unusually high portion of vWF fragments are found. This finding is
compatible with the view that LMW forms of vWF have been partially
or predominantly derived from large multimers by proteolytic
degradation.
[0005] The proteolytic degradation of vWF is a physiological
process in healthy individuals, yet in patients suffering from von
Willebrand disease (vWD) type 2A it may be accelerated, and as a
consequence these patients lack the vWF multimers with the largest
molecular masses. A lack of large vWF multimers and an increased
level of proteolytic fragments are also observed in acquired von
Willebrand disease (vWD) associated with myeloproliferation
syndrome, indicating increased in vivo proteolysis in this
condition as well.
[0006] In patients with thrombotic thrombocytopenic purpura (TTP),
on the other hand, unusually large vWF multimers are detected, and
increased vWF binding to platelets has been demonstrated in these
patients (Wake et. al., New Engl. J. Med., 1982, 307, pp.
1432-1435). Familial TIP is associated with a severe congenital
deficiency of vWF protease, while the presence of vWF-cleaving
proteases inhibiting autoantibodies has been observed in patients
with non-familial TTP.
[0007] The large multimers of vWF associated with TTP normally
disappear after a patient is transfused with normal fresh frozen
plasma. Presently, plasma exchange is the most important treatment
for TTP, although significant side effects have been reported with
this therapy. The existence of a severe congenital deficiency of
vWF protease has been established in patients with familial TTP and
the presence of a vWF-cleaving protease inhibiting autoantibodies
has been observed in patients with non-familial TTP.
[0008] Several proteases have been shown to be able to cleave vWF,
thereby impairing its binding affinity for platelets. However, in
vitro the cleavage of vWF with these proteases in each case results
in cleavage products different from the fragments derived from in
vivo cleavage.
[0009] Thus, for example, while plasmin is capable of cleaving
several peptide bonds in vWF, plasmin-treated vWF retains a high
molecular weight core region retaining about 70% of its platelet
agglutinating activity (determined as ristocetin cofactor). A 34 kD
peptide is split from the N-termini of individual vWF subunits in
the early stages of plasmin treatment, and epitope mapping of such
plasmin-induced fragments show that these fragments originated from
regions of the vWF subunit that are different from the vWF
fragments present in circulating plasma.
[0010] Porcine pancreatic elastase and various serine proteases
released from human leukocytes have also been shown to degrade vWF
proteolytically with a resultant loss of large multimers. Epitope
mapping of the degradation products again indicates that these
fragments also differ from those present in normal plasma and in
vWD type 2A. In addition, a calpain-like protease released from
human platelets has been shown to degrade large vWF multimers and
to create vWF fragments similar to those observed in vivo.
SUMMARY OF THE INVENTION
[0011] We have isolated a composition exhibiting vWF protease
activity that is capable of proteolytically processing vWF in a
physiological manner. Said composition comprises at least one
single peptide chain having a molecular weight between 190 kD and
100 kD as determined by SDS PAGE and comprises the sequence
AAGGILHLELLV. This amino acid sequence is located at the N-terminus
of the peptide chain. The composition comprising the sequence
AAGGHILHLELLV can also be used for isolation, detection or
purification of proteins, i.e. von Willebrand Factor.
[0012] Furthermore, an isolated polypeptide having a molecular
weight between 190 kD and 100 kD according to SDS-PAGE and
comprising the sequence AAGGILHLELLV is also provided. This
sequence is preferably directly followed by the sequence AVG, which
is preferably followed by the sequence
PDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVK
MVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQV
RGVTQLGGACSPTWSCLITEDTGFDLGVTI.
[0013] Another aspect of the present invention is a method of
purifying von Willebrand factor comprising contacting a solution
containing von Willebrand factor with a substrate comprising the
amino acid sequence AAGGILHLELLV under conditions sufficient to
bind von Willebrand factor to the substrate.
[0014] The present invention further comprises, a method of
treating thrombotic diseases using a polypeptide of the present
invention, as shown in FIG. 2.
[0015] In addition, the present invention includes a method of
processing recombinantly produced vWF through the use of the vWF
protease of the present invention, in order to produce a vWF
product.
BRIEF DESCRIPTION OF THE DRAWINGS
[0016] FIG. 1 shows the schematic purification scheme of the vWF
protease containing composition of the present invention.
[0017] FIG. 2 shows the partial nucleotide and amino acid sequence
of the vWF protease of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0018] A composition is provided containing a vWF protease
consisting of a polypeptide chain with an apparent molecular weight
in SDS-PAGE of around 180 kD, around 170 kD, around 160 kD, around
120 kD, around 110 kD or mixtures of these chains, said chain
comprising an amino acid sequence AAGGILHLELLV. Alternatively, this
amino acid sequence can be directly followed by the amino acid
sequence AVG. Furthermore, this sequence is followed by the
sequence PDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHL
VKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNR
QVRGVTQLGGACSPTWSCLITEDTGFDLGVTI.
[0019] The SOS-PAGE was performed under reducing conditions. As is
well known in the art, molecular weight determination using SDS
PAGE results in the detection of apparent molecular masses, which
may be different from the molecular masses of the native,
non-denatured protein.
[0020] Based on a computer search of sequence homologies, the vWF
protease according to the invention shows high homology to the
group of disintegrin and metalloproteinases (ADAM). Members of this
group share several distinct protein modules, including a protease
domain, a disintegrin domain, a cysteine-rich region and an EGF
repeat (Tang B L and Hong W., FEBS, 1999, 445, pp. 223-225). The
nucleotide and amino acid sequence as shown in FIG. 2 comprises at
least 4 axons of the protease portion of the vWF protease of the
present invention.
[0021] Analysis of non-denatured material by mass spectrometry
showed very broad peaks of high molecular weight. No prominent
bands were identified. This finding is in agreement with
appearance, in gel filtration experiments, of 80 kD bands close to
the void volume of. Sephacryl.RTM. S-300, suggesting that the
proteins in this preparation tend to polymerize under physiologic
conditions (a property of clusterin).
[0022] The AAGGILHLELLV sequence is located at the N-terminal
region of the protein. Shortening of the peptide chain occurs at
the C-terminus or via endoproteolytical cleavages. The composition
according to the present invention contains a vWF cleaving protease
that is expressed as a single chain protein.
[0023] Preferably, the composition according to the present
invention further comprises Ca.sup.2+, Sr.sup.2+ and/or Ba.sup.2+
ions. The preparation may comprise calcium ions in a. concentration
of about 1 to 10.sup.6 ions per polypeptide molecule with vWF
protease activity. The preparation according to the present
invention contains vWF protease activity in an essentially purified
form. Preferably, the purified protease preparation from plasma
contains between 0.001% and 1%, preferably 0.002% of the initial
amount of plasma protein, and between 1% and 5%, preferably 2.3% of
the initial enzyme activity, which has been partially inactivated
during the purification procedure. Preferably, the purity is as
high as the relative proportions of polypeptide chains with the vWF
protease activity present in an amount of above 50%, especially
above 80%, most preferred about 90%, of total protein compared to
the vWF protease activity in plasma. Preferably, the preparation
according to the present invention is essentially free of vWF or
vWF fragments, i.e. having a vWF content of below 5%, preferably
below the detection limit of an assay to detect vWF.
[0024] The peptides containing the amino acid sequence AAGGILHLELLV
or AAGGILHLELLVAVG or AAGGILHLELLVAVGPDVFQAHQEDTERYVLTNLNIGAELLRD
PSLGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPEDDTDPGHADLVLYIT
RFDLELPDGNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTI or RRAAGGILHLELLV
AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANL
TSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWS
CLITEDTGFDLGVTI can also be used as tool for detecting proteins
binding to the vWF protease or target sites for ligand development
for detecting, isolating and purifying proteins that bind to the
vWF protease. Preferably the protein to be detected or purified is
vWF.
[0025] These ligands can for example be peptides or peptidomimetics
capable to bind proteins binding to the vWF protease or binding
domains incorporated into antibodies or antibody derivatives (for
example single chain antibodies, miniantibodies, bispecific
antibodies, diabodies etc.).
[0026] Furthermore, the peptide having the amino acid sequence
AAGGILHLELLV or AAGGILHLELLVAVG or AAGGILHLELLV
AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANL
TSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWS
CLITEDTGFDLGVTI or RRAAGGILHLELLV
AVGPDVFQAHQEDTERYVLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANL
TSSLLSVCGWSQTINPEDDTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWS
CLITEDTGFDLGVTI can also be used for the development of anit-vWF
protease antibodies using techniques as known from the art. The
development of these antibodies or antibody derivatives or
peptidomimetics can be accomplished according methods known to the
prior art (Greer J. et al., J. Med. Chem., 1994, Vol. 37, pp.
1035-1054; Harlow E. and Lane D., in "Antibodies. A Laboratory
manual", Cold Spring Harbor Laboratory, 1988, Esser C. and
Radbruchj A. Annu. Rev. Immunol., 1990, vol. 8, pp. 717-735; Kemp
D. S., 1990, Trends Biotechnol., pp. 249-255).
[0027] The present invention relates also to single polypeptide
chains having an apparent molecular weight in reduced SDS-PAGE of
between 190 kD and 100 kD, preferably about 180 kD, more preferably
about 170 kD, in a particularly preferred embodiment about 160 kD,
preferably 120 kD and most preferably about 110 kD, comprising an
N-terminal amino acid sequence AAGGILHLELLV. This sequence is
preferably directly followed by the sequence AVG, which is then
preferably followed by the sequence PDVFQAHQEDTERY
VLTNLNIGAELLRDPSLGAQFRVHLVKMVILTEPEGAPNITANLTSSLLSVCGWSQTINPED
DTDPGHADLVLYITRFDLELPDGNRQVRGVTQLGGACSPTWSCLITEDTGFDLGVTI. In
contrast to the protease entities described by Furlan et al. (1996)
and Tsai (Blood 87 (10) (1996), pp. 4235-4244) the vWF multimerase
entities according to the present invention are much smaller than
the entities described in these documents (around 300 kD (Furlan et
al.), and 200 kD (Tsai), respectively).
[0028] The proteolytic entities provided with the present invention
comprise a physiological vWF cleaving activity which is defined by
(1) the cleaving vWF at the peptide bond 842Ty r-843Met, (2) having
a direct proteolytic activity which converts vWF having a singlet
structure to vWF having a satellite structure, and (3) retaining
activity in the presence of a serine protease inhibitor such as
diisopropyl fluorophosphate (DFP) and in the presence of a calpain
protease inhibitor such as carbobenzyloxy (Z) peptidyl
diazomethylketone inhibitor (Z-Leu-Leu-Tyr-CHN.sub.2). The
proteolytic entities provided with the present invention may also
act indirectly via another effector protein, for example a
protease.
[0029] This single polypeptide chain forms an active vWF cleaving
complex together with a metal ion selected from the group
consisting: Ca.sup.++, Sr.sup.++and Ba.sup.++. The preferred metal
ion is Ca.sup.++. This active complex is able to cleave vWF in a
physiological manner as described above.
[0030] A further aspect of the present invention relates to an
isolated vWF cleavage. complex comprising vWF, a metal ion selected
from the group consisting of Ca.sup.++, Sr.sup.++ and Ba.sup.++ and
one or more single polypeptide chains having vWF protease activity
according to the present invention.
[0031] The vWF proteolytic activity (also termed "vWF protease
activity") of the peptide chains according to the present invention
may be determined by any method described in the art, such as the
method according to Furlan et al. (1996), which is preferred for
the present invention. Further preferred test systems are
described.sup., in International Application No. WO 00/50904. The
test system described in WO 00/50904 is also suitable for the
present vWF protease entities. Alternatively, a collagen binding
assay (as described in EP 816 852) can also be used as a test
system. Preferably, this test is used for screening and diagnostic
purposes.
[0032] A further object of the invention is achieved by providing a
composition containing the vWF protease according to the invention
together with clusterin or an analog or derivative thereof. With
relation to the activity of the protein, the term "derivative" or
"analog" of clusterin refers to proteins that show the same
proteolytic characteristics as the native clusterin protein.
[0033] Clusterin is a heterodimeric glycoprotein consisting of two
non-identical subunits, with a molecular mass of approximately 80
kDa (Rosenberg and Silkensen, J., Int. J. Biochem. Cell Biol.,
1995, vol. 27, pp. 633-645; Tschopp J. and French, L. E., Clinical
and Exp. Immunol., 1994, 97, pp. 11-14). It is produced in a wide
array of tissues and found in most biologic fluids. The physiologic
functions described in the prior art include complement regulation,
lipid transport, sperm maturation, initiation of apoptosis,
endocrine secretion, membrane protection and promotion of cell
interactions.
[0034] It has been found that the unusually high stability of the
vWF protease of the present invention in circulating plasma is
associated with the presence of clusterin. We have found that the
half-life of vWF-cleaving protease activity in vivo is between 1
and 4 days, while other proteases in plasma have half-lives in the
range of seconds to hours. The ratio of clusterin to vWF protease
in a composition according to the present invention is preferably
in a range of 10M:1M to 1M:10M, and more preferably the ratio of
clusterin and vWF is in the equimolar range. In human plasma, the
concentration of vWF-cleaving protease is 2-10 mg/liter whereas
that of clusterin is 50-400 mg/liter plasma (the molar ratio of
vWF-cleaving protease to clusterin in human plasma is about
1:20-1:100).
[0035] Isolation of the composition from either human plasma or
other sources, e.g. supernatants of cell cultures expressing the
polypeptide according to the present invention, milk or other body
fluids of transgenic animals expressing the polypeptide according
to the present invention can be performed by chromatographic means.
Preferably, the purification is performed by a combination of
chromatographic steps including immunoaffinity chromatography, gel
filtration, and ion exchange chromatography. For example, the first
purification step can be immunoaffinity chromatography, the second
step can be gel filtration, followed by one or more additional
immunoaffinity chromatography steps. A further purification can be
performed using ion exchange chromatography, preferably anion
exchange chromatography and at least one affinity chromatography.
Further purification steps can be performed using ion exchange
chromatography, gel filtration and further affinity chromatography
steps.
[0036] As an alternative embodiment, the nucleotide sequence as
shown in FIG. 2 can be used for construoting expression systems
providing appropriate elements for the expression of the DNA which
can then be used for the expression of a polypeptide having vWF
protease activity according to the present invention.
[0037] The expression vector may comprise, for example, in the
direction of transcription, a transcriptional regulatory region and
a translational initiation region functional in a host cell, a DNA
sequence encoding for the polynucleotide expressing a vWF protease
activity according to the present invention and translational and
transcriptional termination regions functional in said host cell,
wherein expression of said nucleic sequence is regulated by said
initiation and termination regions. The expression vector may also
contain elements for the replication of said nucleotide. Examples
of DNA expression vectors are pBPV, pSVL, pRc/CMV, pRc/RSV,
myogenic vector systems (WO 93/09236) or vectors derived from viral
systems, for example from vaccinia virus, adenoviruses,
adeno-associated virus, herpes viruses, retroviruses or baculo
viruses.
[0038] The expression vector containing the nucleic acid which
encodes the polypeptide having vWF protease activity according to
the present invention can be used to transform host cells which
then produce said polypeptide. The transformed host cells can be
grown in a cell culture system to produce said polypeptide in
vitro. The host cells preferably excrete the polypeptide having vWF
protease activity into the cell culture medium from which it can be
prepared.
[0039] The host cells may be cells derived from the body of a
mammal, for example fibroblasts, keratinocytes, hematopoietic
cells, hepatocytes or myoblasts, which are transformed in vitro
with an expression vector system carrying a nucleic acid according
to the present invention and re-implanted into the mammal. The
polypeptide according to the present invention encoded by said
nucleic acid will be synthesized by these cells in vivo and they
will exhibit a desired biological activity in the mammal.
[0040] The nucleic acid encoding the polypeptide according to the
present invention may also be used to generate transgenic animals,
which express said polypeptide proteins in vivo. In one embodiment
of this specific application, the transgenic animals may express
the polypeptide having vWF protease activity in endogenous glands,
for example in mammary glands from which the said proteins are
secreted. In the case of the mammary glands, said proteins having
vWF protease activity are secreted into the milk of the animals
from which said proteins can be prepared. The animals may be mice,
cattle, pigs, goats, sheep, rabbits or any other economically
useful animal.
[0041] The vWF protease composition of the present invention can be
used, for example, to process recombinantly produced vWF.
Recombinant vWF (r-vWF) can be produced in CHO cells e.g. according
to FEBS. Letter 375, 259-262 (1995). The r-vWF recovered in this
manner is available as a mature vWF and has a singlet structure,
i.e. it differs from plasma-derived vWF, which always has a
characteristic satellite structure when examined on 2% SDS agarose
gels. In International Patent Application No. WO 96/10584 describes
that r-vWF is comprised of multimers with high structural integrity
which is retained even after purification and treatment for the
inactivation of viruses. The intact structure of the r-vWF is
defined by a result of electrophoretic analysis consisting of
multimer bands with an absence of satellite bands. To prepare an
r-vWF preparation having a structure more closely corresponding to
that of plasma-derived vWF from r-vWF with singlet structure, r-vWF
is treated with the vWF protease composition of the present
invention.
[0042] According to a further aspect of the present invention, the
amino acid sequence and nucleotide sequence as shown in FIG. 2 can
also be used for the production of a preparation for the
prophylaxis and therapy of diseases that show supranormal vWF
content or an increased level of high-rnolecular weight vWF in
patients. This can result in thromboses and thromboembolic
diseases. For example, thrombotic throbocytic purpura (TTP),
Henoch-Schonlein purpura, preeclampsia, neonatal thrombocytopenia
or haemolytic-uremic syndrome. By administering an effective dose
of a polypeptide having a vWF protease activity and having an amino
acid sequence as shown in FIG. 2, this can lead to reduction of the
content of high molecular weight vWF multimers in the patients,
resulting in effective therapy of these diseases. The invention is
described in the following examples, without being limited
thereto.
EXAMPLES
Example 1: Method for Isolating vWF-Cleaving Proteolytic
Peptides
1.1. Preparation of an IgG-eTTP-Coupled Affinity Gel
[0043] The IgG-eTTP was isolated by aid of a 20 ml protein
A-Sepharose.RTM. (diameter 1.6 cm) in TBS, pH 7.4.. Pheresis plasma
of a patient suffering from acquired TTP ("erworbenes" TTP; eTTP),
which previously had been assayed for its inhibitor content
relative to the vWF-cleaving protease was applied to the column in
a volume of 50 ml. After subsequent rinsing with TBS, pH 7.4, the
bound IgGs were step wise eluted with citrate, 0.1 M, pH 4.0, and
glycine, 0.1 M, pH 2.7. The fractions immediately were brought to a
physiological pH by adding Tris, 1.5 M, pH 8.8, and dialysed
against TBS, pH 7.4. The Affi-Gel.RTM. Hz was coupled according to
the producer's instructions with the IgG-eTTP which had been washed
out of the protein A-Sepharose.RTM. with a pH of 4.0. The column
material prepared in this manner first was washed as prescribed,
subsequently it was washed 3 times alternatingly with 50 ml of
buffer B and 200 ml of buffer A (chapter 1.7). Prior to use,
intensive rinsing with buffer A was carried out in each
instance.
1.2 First Step
[0044] As the starting material, 100 ml of pooled CPD plasma which
had come from at least three donors and had been stored at
-20.degree. C., was used after centrifuging at 2,500 rpm (1,100 g)
for 5 min. At a relatively low flow rate (FR: 30 ml/h), the plasma
was loaded on a 200 ml chromatographic column with IgG-eTTP
Affi-Gel.RTM. Hz (hydrazide, diameter 2.6 cm) which had been
equilibrated in buffer A. After washing with at least 400 ml of
buffer A over night at the same flow rate, a 200 ml desalting gel
filtration column (Bio-Gel.RTM. P-6DG, diameter 2.6 cm) and a 10 ml
protein G-Sepharose.RTM. (diameter 1.6 cm), which previously also
had been rinsed with buffer A, was connected thereto. After the
flow rate had been increased to 100 ml/h, the proteins bound to
Affi-Gel Hz were eluted directly with 50 ml of buffer B onto the
Bio-Gel.RTM. P-6DG so as to remove from the proteins the NaSCN that
had been in buffer B. The proteins which had been eluted from the
desalting column prior to the NaSCN were led through the protein G
Sepharose.RTM. without interruption, where they were freed from the
IgGs. Here, the flow rate was lowered to 50 ml/h so as to extend
the dwelt time of the proteins in the 10 ml column. For
regeneration, the protein G-Sepharose.RTM. was shortly washed with
buffer C, and the eluted IgG fraction was stored for analysis.
[0045] The first step was carried out 8 times before the collected
fractions which had been frozen at -20.degree. C. were pooled and
further processed.
1.3 Second Step
[0046] The pooled fractions from 8 chromatographies of the first
step were diluted 1:1 with H.sub.2O so as to obtain an ionic
strength at which the desired proteins would bind to the anion
exchange column (High Q Support.RTM.). The sample whose volume was
from 1,500 to 1,800 ml, depending on the charge used, was checked
for its pH and its ionic strength and applied over night at a FR of
90 ml/h through a 50 ml column with Therasorb.RTM. (diameter 1.6
cm) onto a 5 ml High Q Support.RTM. (diameter 1.6 cm). Both,
Therasorb and High Q Support.RTM. had previously been equilibrated
in buffer D. After washing with approximately 150 ml of buffer D,
the Therasorb was disconnected, and the 25 ml Lentil Lectin
Sepharose.RTM. (diameter 1.6 cm) which had been equilibrated in
buffer E was connected to follow the High Q Support.RTM.. At a FR
of 60 ml/h, the proteins bound to High Q Support were immediately
eluted with buffer E directly to the Lentil Lectin-Sepharose.RTM..
The proteins which bound to the Lentil Lectin-Sepharose.RTM. could
be eluted in two steps with buffers G and H and could be collected.
The proteins which had remained bound to Therasorb and High Q
Support.RTM. were washed out with buffer C or buffer F,
respectively, and discarded after an analysis.
[0047] For regeneration, before being used, the Lentil
Lectin-Sepharose.RTM. in each case was rinsed according to the
producer's instruction 3 times alternatingly with 20 Mt each of
buffers I and J, the High Q Support was rinsed successively with 10
ml each of NaOH 1N and NaCl 1M.
1.4 Third Step
[0048] The pooled fractions which had been eluted from the Lentil
Lectin-Sepharose.RTM. with buffer H were dialysed three times for a
total: of 4 h, each against 1 l of buffer D, and again applied to
the High Q Support at a flow rate of 60 ml/h. Connected
thereinfront was a 5 ml heparin-Sepharose (diameter 1.4 cm), which
likewise had been equilibrated in buffer D. After the application
of the sample, it was rinsed with approximately 50 ml of buffer D,
the heparin-Sepharose was disconnected, and a 500 ml Sephacryl.RTM.
S-300 HR (diameter 2.6 cm), which had been equilibrated in buffer
L, was connected thereto. The proteins bound to High Q Support were
directly eluted to the gel filtration column with 10 ml of buffer
K. The exclusion chromatography was effected at a flow rate of 42
ml/h, and the fractions were collected at 7 ml each. The proteins
which were more strongly bound to High Q Support.RTM. were again
eluted with buffer F, those which remained adhered to the
heparin-Sepharose, with buffer K.
1.5 Fourth Step
[0049] The pool of the active fractions from the third step was
applied without treatment at a FR of 10 ml/h to a 1 ml
anti-.alpha..sub.2-macroglobulin column (flow rate 0.7 cm) which
had been equilibrated in buffer L. The
anti-.alpha..sub.2-macroglobulin column was prepared by
immobilization according to the instructions, of
rabbit-anti-.alpha..sub.2-macroglobulin antibodies at a
concentration of 4.9 mg/ml on CNBr-activated Sepharose. The
proteins bound thereon were eluted with NaSCN 3M in buffer L and
with buffer C and stored for analysis.
1.5. Materials
TABLE-US-00001 [0050] buffer A Tris 10 mM pH 7.4 NaCl 0.15M
Na.sub.3-citrate 1 mM Na acid 0.02% buffer B NaSCN 3.0M pH 7.4 in
buffer A buffer C glycine 0.1M pH 2.7 Na acid 0.02% buffer D Tris
10 mM pH 7.4 NaCl 75 mM buffer E Tris 20 mM pH 7.4 NaCl 0.5M
MnCl.sub.2 1 mM buffer F Tris 10 mM pH 7.4 NaCl 1.0M buffer G Tris
20 mM pH 7.4 NaCl 0.5M Methyl-.alpha.-D-mannopyranoside 30 mM
buffer H Tris 20 mM pH 7.4 NaCl 0.5M
Methyl-.alpha.-D-mannopyranoside 0.3M buffer I Tris 20 mM pH 8.5
NaCl 0.5M buffer J Na acetate 20 mM pH 5.5 NaCl 0.5M buffer K Tris
10 mM pH 7.4 NaCl 0.5M buffer L (TBS) Tris 10 mM pH 7.4 NaCl
0.15M
Chromatographic Materials
TABLE-US-00002 [0051] affi-gel hydrazide gel .RTM.: for
immobilizing specific Bio-Rad, Hercules, CA, USA IgG's
anti-.alpha..sub.2-macroglobulin column: isolation of applicant's
own production (see 1.5): .alpha..sub.2-macroglobulin
rabbit-anti-human-.alpha..sub.2-macroglobulin antibody on CNBr
activated Sepharose 4B; 4.9 mg/ml Bio-Gel .RTM. P6-DG, medium: gel
filtration Bio-Rad with exclusion limit .gtoreq. 6 kDa CNBr
activated Sepharose 4B .RTM.: for Amersham Pharmacia Biotech,
Uppsala, immobilizing proteins S heparin Sepharose, HITrap .RTM. 5
ml: Amersham Parmacia affinity chromatography: binds various
proteins High Q Support .RTM., Macro-Prep: strong Bio-Rad anion
exchanger IgG-eTTP Affi-gel Hz: for binding vWF-protease
applicant's own production (see 1.1.): IgG- eTTP on Affi-gel Hz
hydrazide Lentil Lectin-Sepharose 4B: affinit Amersham Pharmacia
chromatography: binds to sugar residues o proteins protein A
Sepharose .RTM. CL-4B. binds IgG of Amersham Pharmacia type 1, 2
and 4 protein G Sepharose .RTM. 4FF: isolation of IgGs Amersham
Pharmacia of all types Sephacryl .RTM. S-300 HR: gel filtration for
MWs Amersham Pharmacia 10,000 to 1,500,000 Therasorb: coupled with
sheep-anti-human-Ig Serag-Wiessner, Naila, D antibodies: isolation
of human immunoglobulins
1.6 Fifth Step
[0052] Alternatively, or in addition to step four, an
anti-clusterin column chromatography as a further step can be
applied. The samples were prepared identically to the
anti-.alpha.2-macrogluobulin-column using anti-clusterin
antibodies.
2. SDS-Page Reduced/Non-Reduced
SDS-Polyacrylamide Gel-Electrophoresis (SDS-PAGE)
[0053] SDS-PAGE was done according to Lammli. The separating gels
were prepared having a size of 13.5 cm height, 15 cm width and 3 mm
thickness, having the composition as follows:
[0054] Concentration of SDS-Polyacrylamide gel for a gradient gel
of 4% to 12%:
TABLE-US-00003 Acrylamide 4% 12% N,N'-Methylenebisacrylamide 0.107%
0.32% Tris (Tris(hydroxymethyl)aminomethane) 0.4M 0.4M APS
(Ammoniumperoxydisulfate) 0.03% 0.03% SDS (Sodium Dodecyl Sulfate)
0.1% 0.1% Temed 0.067% 0.067%
(N,N,N',N'-Tetramethylethylenediamine) pH 8.7 pH 8.7
[0055] 30 ml of each of the 4% and 12% solutions, were poured
between two glass plates.
[0056] After polymerization, the stacking get was prepared, having
a height of 3 cm and having 16 slots. The volume of each slot was
150 .mu.l.
Stacking Gel
TABLE-US-00004 [0057] Acrylamide 3% N,N'-Methylenebisacrylamide
0.08% Tris 0.1M APS 0.03% SDS 0.1% Temed 0.2% pH 6.8
[0058] 100 .mu.l probe were mixed with 50 .mu.l buffer for the
SDS-PAG and incubated 20 minutes at 60.degree. C. Probes that had
to be reduced were mixed with DTT (1,4-Dithio-DL-threitol), 65 mM
before the solution was heated up.
Buffer for the SDS-PAGE
TABLE-US-00005 [0059] Tris 0.15M SDS 4% Glycerin-87% 30% Bromine
phenol blue few amounts pH 6.8
[0060] After heating, the probes were centrifuged, loaded onto the
slots of the SDS PAG and covered with electrophoresis buffer.
Electrophoresis was run over night in a vertical chamber system,
using 60 V voltage.
Electrophoresis Buffer
TABLE-US-00006 [0061] Tris 50 mM Glycine 0.38M EDTA (Titriplex III:
ethylen- 2 mM dinitrilo tetra acetic acid- disodium salt
-dihydrate) SDS 0.1% standard-pH 8.3
Silver Staining
[0062] The gels (13.5.times.15.times.0.3 cm) were put into a tray
containing a mixture of methanol (25%), acetic acid (7.5%), water
(65.5%) and glycerin-87% (2%) (fixing solution) for at least 3
hours. Subsequently, the gets were rinsed 4-times with 200 ml water
for 1 hour. Then the get was put into a sodium thio sulfate
solution (0.02%), washed twice with water (1 min) and incubated
2-times 20 minutes with silver nitrate (0.1%) in water under
constant shaking.
[0063] After rinsing with water for two times, the gel was shaken
in a developing solution, consisting of sodium carbonate (2.5%) and
formaldehyde-37% (0.04%) in water. The reaction was stopped with
the fixing solution, as soon as the proteins were visible as gray
to brown bands.
Example 2: Affinity Purification of von Willebrand Factor (vWF)
[0064] The peptide with the sequence AAGGILHLELLV was synthesized
on a solid-phase support following the method of Barany, G and
Merrifield, R. B. (1980) Solid-phase Peptide Synthesis, in The
Peptides vol. 2 (Gross, E. and Meienhofer, J., eds) Academic, New
York. After cleavage and de-protection of the peptide, the peptide
was purified by ion-exchange chromatography. The peptide was
characterized by reverse phase HPLC on a C8 silica column with
gradient elution in trifluoro acetic acid with acetonitrile. The
peptide showed no major byproducts.
[0065] The peptide was solubilized in a concentration of 5 mg/mL in
0.1 molar phosphate buffer pH 7.5 and incubated with a
pre-activated gel suitable for affinity chromatography (Actigel,
ALD-Superflow, Sterogene). Prior to coupling of the peptide to the
gel the pre-activated matrix was excessively washed with the same
phosphate buffer. One volume of the pre-washed gel was then mixed
with one volume of the peptide solution to be immobilized and
subsequently 0.1 volume portions of a solution of 0.1 molar
cyanoborohydride (NaCNBH.sub.3) in 0.1 molar phosphate buffer pH
7.5. The gel was suspended in this solution and shaked for 15 hours
at room temperature. Subsequently the gel was washed on a sinter
funnel with a 10-fold volume of the phosphate buffer containing 150
mmolar NaCl and with 5 volumes of the phosphate buffer containing 2
molar NaCl. Then the gel was equilibrated with an access of 0.1
molar phosphate buffer pH 7.0.
[0066] The gel was then transferred into a chromatographic column
having a dimension of diameter to get bed height of 1:4. By
determining the peptide concentration the solution of the
incubation supernatant after separation from the gel and the
washing solutions the amount of peptide coupled to the affinity
matrix was calculated. The coupling rate was 85%.
[0067] The gel was subsequently used to purify vWF from a Factor
VIII (FVIII)/vWF complex. A FVIII/vWF complex concentrate was
produced according to EP 0 270 516 containing vWF in a
concentration of 260 U vWF:Ag/ml and a specific activity of 13.5 U
vWF:Ag/mg Protein. The concentrate was diluted with 20 mM phosphate
buffer pH 7.0 to a final vWF concentration of 6 U vWF:Ag/mL. A
volume of 20 ml of this solution was subjected to the affinity
column with immobilized peptide described above. After washing the
column with 10 ml of the phosphate buffer the vWF specifically
bound to the peptide ligand was eluted by a linear gradient from
0-2 mol/l NaCl in phosphate buffer at a flow rate of 1 ml/minute.
Fractions of 1 ml were collected and their optical density was
determined at 280 nm. All fractions were measured for their content
of vWF antigen determined by a specific ELISA method (Asserachrom
vWF, Boehringer, Mannheim). Measurement showed a specific peak of
vWF eluting from the peptide at a NaCl concentration of 100 mmol/l,
while most of the protein measured by UV-absorption eluted prior to
the vWF fraction with the washing buffer. The vWF containing
fractions were pooled and measured for vWF activity. The vWF in
this pool had a specific activity of 95 U vWF/mg protein and was
essentially free from other proteins.
Example 3: Anti-Peptide Antibodies
[0068] The peptide with the sequence AAGGILHLELLV was synthesized
and purified as described in example 2. The peptide was then used
to immunize 3 months old BALB/c mice with the following protocol: A
primary subcutaneous injection of 100 .mu.g peptide antigen
emulsified in Freund's complete adjuvant in 100 .mu.l followed by
intra-peritoneal boosts of 100 .mu.g peptide antigen in phosphate
buffered saline at monthly intervals.
[0069] The anti-peptide titer was tested by routine ELISA method
using. purified peptide as screening antigen. After the final boost
the spleens were taken from the mice for dell fusion. Cell fusion
was carried out according to a standard protocol originally
described by Kohler G. and Milstein C. 1975, Nature 256:495.
Anti-peptide antibodies producing hybridoma cell lines were
screened by standard techniques with the purified peptide as
screening antigen essentially based on a conventional ELISA
methodology. After cloning a cell line could be isolated with a
high expression level of an antibody specific for the screening
peptide with the sequence AAGGILHLELLV. This cell line was cultured
on serum-free culture medium and grown to high density. The
supernatant of the cell culture was harvested by centrifugation to
remove cells and the monoclonal antibody containing supernatant was
concentrated by ultra-diafiltration and conditioned for further
use.
[0070] The monoclonal antibody obtained had a high selectivity for
the vWF cleaving protease as described by Furlan et al. 1996, Blood
87:4223-4234. This monoclonal antibody was immobilized to a
polystyrene ELISA plate in a carbonate/bi-carbonate buffer, 0.05
molar, pH 9.6, at a concentration of 5 .mu.g immunoglobuline/ml
overnight (16 hours) at 4.degree. C., with each 100 .mu.l of
coating solution per well. The coating solution was removed from
the wells and replaced by a solution of bovine serum albumin (BSA)
at a concentration of 100 .mu.g/ml at a volume of 100 .mu.L per
well, for 2 hours. The BSA solution was removed and the wells were
washed with phosphate buffered saline. The pre-coated plates were
then incubated with either samples of platelet poor plasma from
healthy human plasma donors or platelet poor plasma from patients
with an unclear diagnosis of either thrombotic thrombocytopenic
purpura (TTP) or hemolytic uremic syndrome (HUS). After incubation
of the plasma samples with the antibody coated ELISA plates as in a
routine sandwich ELISA system, after 3 hours the plasma was removed
from the wells. Wells were washed with phosphate buffered saline
and incubated with the monoclonal antibody directed against the
peptide with the sequence AAGGILHLELLV, conjugated with horse
radish peroxidase following the method of Wilson, M. B. and Nakane,
P. K. (1978) In Immunofluorescence and Related Staining Techniques.
Knapp, W. Holubar, K. and Wick, G (eds), Elsevier/North Holland,
Amsterdam, p. 215, and detected by the OPT reagent as described by
Cathy D. and Raykundalia Ch. (1989) ELISA and related enzyme
immunoassays, in Antibodies II a practical approach. Cathy D (ed),
IRL Press Eynsharri Oxford England, p. 97.
[0071] Based on the level of the samples from the healthy human
plasma donors a normal range was established. Plasmas from patients
with HUS had a vWF protease activity equivalent to healthy humans
while patients with TTP had a decreased protease activity as
confirmed by an assay based on a different assay principle as
described in WO00/509904.
Example 4: Amino Acid Sequencing and Amino Acid Analysis of the vWF
Protease
[0072] The final protein preparation from the third step of
isolation was electrophoresed on a 1.5 mm-thick SDS-polyacrylamide
gel according to Laemmli (Laemmli UK., Nature, 1970, 227, pp.
680-685) A gradient of 4 to 12% polyacrylamide was used for
fractionation of high molecular weight proteins, and a gradient of
8 to 12% polyacrylamide for low molecular weight proteins. After
electrophoresis under non-reducing or reducing conditions (final
concentration 65 mmol/l dithiotreitol), the proteins were blotted
onto PVDF-membranes and stained, for 2 min with 0.25% Coomassie
Blue in 45% methanol, 9% acetic acid and 46% H.sub.2O. After
rinsing with: a Mixture of 50% methanol, 10% acetic acid and 40%
H.sub.2O, the visible protein bands were cut out and analyzed on a
Procise-cLC Sequencer (Foster City, Calif.) at the Chemical
Institute of the University of Bern.
[0073] The N-terminal amino acid sequence of polypeptide bands
separated by SDS-PAGE of purified vWF-cleaving protease is shown in
table 1:
TABLE-US-00007 Molecular weight Amino Acid sequence 350 kDa
unreduced Ser-Val-Ser-Gly-Lys- Pro-Gln-Tyr-Met-Val* 150 kDa unred.
Ala-Ala-Gly-Gly-Ile 140 kDa unred. Ala-Ala-Gly-Gly-Ile 130 kDa
unred. Ala-Ala-Gly-Gly-Ile 110 kDa unred. Ala-Ala-Gly-Gly-Ile-
Leu-His-Leu-Glu 70 kDa unred. Asp/Ser-Gln/Leu-Thr/
Met-Val/Pro-Ser/Phe** 180 kDa reduced Ala-Ala-Gly-Gly-Ile-
Leu-His-Leu-Glu 170 kDa reduced Ala-Ala-Gly-Gly-Ile 160 kDa reduced
Ala-Ala-Gly-Gly-Ile- Leu-His-Leu-Glu-Leu- Leu-Val-Ala-Val-Gly 120
kDa reduced Ala-Ala-Gly-Gly-Ile- Leu-His-Leu-Glu-Leu-
Leu-Val-Ala-Val-Gly 40 kDa reduced Asp-Gln-Thr-Val-Ser**
*identified as .alpha.2-macroglobulin **identified as clusterin
[0074] Analysis of the composition of the amino acids was performed
from the same sample as used for amino acid sequencing. The protein
bands were hydrolyzed in the gas phase over 6 N HCl for 22 hours'
at 110.degree. C. and the amino acids were determined by
high-performance liquid chromatography. Four unreduced polypeptide
bands from SDS-PAGE of purified vWF-cp with M.sub.r 150, 140, 130,
and 110 kDa were analyzed
[0075] The results are shown in Tab. 2:
TABLE-US-00008 No. residues/100 residues Amino acid 150 kDa 140 kDa
130 kDa 110 kDa Asx 6.7 7.0 7.4 8.3 Glx 12.2 12.0 12.8 11.8 Ser 8.4
8.9 8.8 9.2 Gly 11.8 12.1 12.1 12.9 His 2.5 2.3 2.5 2.4 Arg 8.3 7.6
8.1 7.2 Thr 5.6 5.5 5.6 5.7 Ala 10.1 9.5 9.6 8.2 Pro 8.9 8.5 8.3
8.1 Tyr 2.1 2.7 2.3 2.4 Val 7.0 6.9 6.7 6.5 Ile 2.7 2.9 2.6 3.0 Leu
10.0 9.9 9.1 9.7 Phe 2.6 2.8 2.6 3.2 Lys 1.0 1.3 1.3 1.4
Example 5: Search on Chromosome 9 Clone RP11-224N20 for Potential
Exons of the vWF-Protease
[0076] The coding region of the N-terminus of the activated vWF
protease (aminoacids A-A-G-G-I-L-H-L-E-L-L-V-A-V-G) was found on
Chromosome 9 clone RP11-224N20 bases 156653 to 156697. Thus the
nucleotide sequence from base 150001 to 185911 was screened for
potential exons. Consecutive overlapping genome-segments with
various lengths (1500 bases-5000 bases) were analysed using search
engines that were queried via the internet-explorer. The genomic
sequence segments, its translations and the results of the search
were managed using the `Vectors NTI Suite1 v.5.2` computer-program
(Informax Inc., USA).
[0077] The first four exons of the search were translated into the
corresponding amino add sequence and these sequences were searched
for homologies. This search revealed that each sequence displays
high homology with the amino acid sequence of the family of human
disintegrin and metalloproteinases with thrombospondin motifs
(ADAM-TS).
[0078] By alignments performed with the `Vectors NTI Suite1
v.52-AlignX` program (Informax Inc., USA), further potential exons
were identified that encode for amino acid sequences that are
homologous to segments of the human ADAM-TS sequences. Exons
potentially encoding for the entire proteinase domain, for parts of
the disintegrin like domain, the thrombospondin motif, the
cystein-rich domain, as well as for three potential thrombospondin
submotifs or a new ADAM-TS proteinase were thus identified. The
succession of the exons on the genomic sequence was found to be
consistant with the succession of the corresponding amino acid
segments on the ADAM-TS consensus sequence.
Example 6: Cloning of the Gene Expressing the vWF-Protease Gene
[0079] Human salivary gland poly A+ RNA was purchased from
Clontech. First strand cDNA was, obtained using Expand reverse
transcriptase (Roche) and oligo d(T) primer according to the
manufacturer's instructions. PCR was performed using
5'CGGCGGGATCCTACACCTGG 3' and 5'AATGGTGACTCCCAGGTCGA 3' as primers
with 10 ng of salivary gland cDNA as template and 10 U of Hot Star
Tag polymerase (Quiagen). The thermal cycling parameters were an
initial incubation at 94.degree. C. for 15 minutes followed by 45
cycles of 94.degree. C. (50 sec), 50.degree. C. (50 sec),
72.degree. C. (2 min). PCR products were directly sequenced in both
directions using the BigDye Terminator Cycle Sequencing Ready
Reaction Kit (PerkinElmer Life Science).
[0080] The obtained DNA sequence was used to scan the genomic data
base using BLAST (basic local alignment search tool) programs and
matched to the chromosome 9 clone RP11-224N20. DNA sequence was
translated to amino acids sequence using ExPASy proteomic tools.
The DNA and translated amino acid sequences corresponding to 4
putative exons of chromosome 9q34 are shown in FIG. 2.
Sequence CWU 1
1
15112PRTHomo sapiens 1Ala Ala Gly Gly Ile Leu His Leu Glu Leu Leu
Val 1 5 10 2133PRTHomo sapiens 2Pro Asp Val Phe Gln Ala His Gln Glu
Asp Thr Glu Arg Tyr Val Leu 1 5 10 15 Thr Asn Leu Asn Ile Gly Ala
Glu Leu Leu Arg Asp Pro Ser Leu Gly 20 25 30 Ala Gln Phe Arg Val
His Leu Val Lys Met Val Ile Leu Thr Glu Pro 35 40 45 Glu Gly Ala
Pro Asn Ile Thr Ala Asn Leu Thr Ser Ser Leu Leu Ser 50 55 60 Val
Cys Gly Trp Ser Gln Thr Ile Asn Pro Glu Asp Asp Thr Asp Pro 65 70
75 80 Gly His Ala Asp Leu Val Leu Tyr Ile Thr Arg Phe Asp Leu Glu
Leu 85 90 95 Pro Asp Gly Asn Arg Gln Val Arg Gly Val Thr Gln Leu
Gly Gly Ala 100 105 110 Cys Ser Pro Thr Trp Ser Cys Leu Ile Thr Glu
Asp Thr Gly Phe Asp 115 120 125 Leu Gly Val Thr Ile 130 3444DNAHomo
sapiens 3gctgcaggcg gcatcctaca cctggagctg ctggtggccg tgggccccga
tgtcttccag 60gctcaccagg aggacacaga gcgctatgtg ctcaccaacc tcaacatcgg
ggcagaactg 120cttcgggacc cgtccctggg ggctcagttt cgggtgcacc
tggtgaagat ggtcattctg 180acagagcctg agggtgcccc aaatatcaca
gccaacctca cctcgtccct gctgagcgtc 240tgtgggtgga gccagaccat
caaccctgag gacgacacgg atcctggcca tgctgacctg 300gtcctctata
tcactaggtt tgacctggag ttgcctgatg gtaaccggca ggtgcggggc
360gtcacccagc tgggcggtgc ctgctcccca acctggagct gcctcattac
cgaggacact 420ggcttcgacc tgggagtcac catt 4444148PRTHomo sapiens
4Ala Ala Gly Gly Ile Leu His Leu Glu Leu Leu Val Ala Val Gly Pro 1
5 10 15 Asp Val Phe Gln Ala His Gln Glu Asp Thr Glu Arg Tyr Val Leu
Thr 20 25 30 Asn Leu Asn Ile Gly Ala Glu Leu Leu Arg Asp Pro Ser
Leu Gly Ala 35 40 45 Gln Phe Arg Val His Leu Val Lys Met Val Ile
Leu Thr Glu Pro Glu 50 55 60 Gly Ala Pro Asn Ile Thr Ala Asn Leu
Thr Ser Ser Leu Leu Ser Val 65 70 75 80 Cys Gly Trp Ser Gln Thr Ile
Asn Pro Glu Asp Asp Thr Asp Pro Gly 85 90 95 His Ala Asp Leu Val
Leu Tyr Ile Thr Arg Phe Asp Leu Glu Leu Pro 100 105 110 Asp Gly Asn
Arg Gln Val Arg Gly Val Thr Gln Leu Gly Gly Ala Cys 115 120 125 Ser
Pro Thr Trp Ser Cys Leu Ile Thr Glu Asp Thr Gly Phe Asp Leu 130 135
140 Gly Val Thr Ile 145 515PRTHomo sapiens 5Ala Ala Gly Gly Ile Leu
His Leu Glu Leu Leu Val Ala Val Gly 1 5 10 15 6150PRTHomo sapiens
6Arg Arg Ala Ala Gly Gly Ile Leu His Leu Glu Leu Leu Val Ala Val 1
5 10 15 Gly Pro Asp Val Phe Gln Ala His Gln Glu Asp Thr Glu Arg Tyr
Val 20 25 30 Leu Thr Asn Leu Asn Ile Gly Ala Glu Leu Leu Arg Asp
Pro Ser Leu 35 40 45 Gly Ala Gln Phe Arg Val His Leu Val Lys Met
Val Ile Leu Thr Glu 50 55 60 Pro Glu Gly Ala Pro Asn Ile Thr Ala
Asn Leu Thr Ser Ser Leu Leu 65 70 75 80 Ser Val Cys Gly Trp Ser Gln
Thr Ile Asn Pro Glu Asp Asp Thr Asp 85 90 95 Pro Gly His Ala Asp
Leu Val Leu Tyr Ile Thr Arg Phe Asp Leu Glu 100 105 110 Leu Pro Asp
Gly Asn Arg Gln Val Arg Gly Val Thr Gln Leu Gly Gly 115 120 125 Ala
Cys Ser Pro Thr Trp Ser Cys Leu Ile Thr Glu Asp Thr Gly Phe 130 135
140 Asp Leu Gly Val Thr Ile 145 150 710PRTHomo sapiens 7Ser Val Ser
Gly Lys Pro Gln Tyr Met Val 1 5 10 85PRTHomo sapiens 8Ala Ala Gly
Gly Ile 1 5 99PRTHomo sapiens 9Ala Ala Gly Gly Ile Leu His Leu Glu
1 5 1010PRTHomo sapiens 10Asp Ser Gln Leu Thr Met Val Pro Ser Phe 1
5 10 1115PRTHomo sapiens 11Ala Ala Gly Gly Ile Leu His Leu Glu Leu
Leu Val Ala Val Gly 1 5 10 15 125PRTHomo sapiens 12Asn Gln Thr Val
Ser 1 5 1320DNAArtificial Sequencesynthetic oligo primer
13cggcgggatc ctacacctgg 201420DNAArtificial Sequencesynthetic oligo
primer 14aatggtgact cccaggtcga 2015136PRTHomo sapiens 15Ala Val Gly
Pro Asp Val Phe Gln Ala His Gln Glu Asp Thr Glu Arg 1 5 10 15 Tyr
Val Leu Thr Asn Leu Asn Ile Gly Ala Glu Leu Leu Arg Asp Pro 20 25
30 Ser Leu Gly Ala Gln Phe Arg Val His Leu Val Lys Met Val Ile Leu
35 40 45 Thr Glu Pro Glu Gly Ala Pro Asn Ile Thr Ala Asn Leu Thr
Ser Ser 50 55 60 Leu Leu Ser Val Cys Gly Trp Ser Gln Thr Ile Asn
Pro Glu Asp Asp 65 70 75 80 Thr Asp Pro Gly His Ala Asp Leu Val Leu
Tyr Ile Thr Arg Phe Asp 85 90 95 Leu Glu Leu Pro Asp Gly Asn Arg
Gln Val Arg Gly Val Thr Gln Leu 100 105 110 Gly Gly Ala Cys Ser Pro
Thr Trp Ser Cys Leu Ile Thr Glu Asp Thr 115 120 125 Gly Phe Asp Leu
Gly Val Thr Ile 130 135
* * * * *